ea0022p566 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010
Simoes Helder
, Lalanda Carolina
, Oliveira Manuela
, Raposo Luis
, Duarte Sequeira
, Saraiva Machado
Introduction: TSH-secreting adenomas represent <2% of pituitary tumors. Surgery and/or radiotherapy are primary treatment options. Somatostatin analogues and also dopamine agonists, represent valuable alternatives or adjuvant therapies.Objective: To report a case of euthyroidism and tumor stability achieved in a TSH-secreting pituitary macroadenoma, treated with octreotide-LAR, as first line therapy, and then added cabergoline. To review the efficacy...